Business, energy, technology, markets and global industry news from Business News Today

primary central nervous system lymphoma

PharmaDeviceNews primary central nervous system lymphoma
Curis reports expanded emavusertib clinical responses in relapsed or refractory primary central nervous system lymphoma, strengthening interest in the investigational combination treatment strategy. Representative image.
Pharma & Biotech

Curis expands emavusertib PCNSL response pool as TakeAim CLL enrolment accelerates

Curis reports updated emavusertib responses in PCNSL and faster CLL enrolment, while durability, safety and funding remain critical tests.

Read More
Pharma & Biotech

Why Deciphera Pharmaceuticals’ tirabrutinib NDA matters for the future of CNS lymphoma therapy

FDA accepts tirabrutinib NDA for relapsed or refractory PCNSL. Find out what this means for CNS lymphoma treatment and regulatory strategy.

Read More
Representative image: Illustration depicting CAR T-cell therapy research in the central nervous system, reflecting the FDA’s removal of Yescarta’s CNS limitation for relapsed or refractory primary CNS lymphoma.
Pharma & Biotech

FDA removes CNS limitation for Yescarta, reshaping the regulatory boundary for CAR T therapy in primary CNS lymphoma

Kite Pharma, a subsidiary of Gilead Sciences, has received approval from the U.S. Food and Drug Administration to update the prescribing information for Yescarta axicabtagene ciloleucel by removing the prior limitation of use in patients with relapsed or refractory primary central nervous system lymphoma. The decision follows safety findings from an investigator sponsored Phase 1

Read More